Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

Core Insights - Ocular Therapeutix will present detailed results from the SOL-1 Phase 3 clinical trial of AXPAXLI™ for wet age-related macular degeneration at the 49th Macula Society Annual Meeting on February 27, 2026 [1][2] - An investor webcast is scheduled for March 2, 2026, to discuss the SOL-1 data presented at the meeting [1][3] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience [5] - AXPAXLI™ (OTX-TKI) is an investigational product candidate for retinal diseases, currently in Phase 3 trials for wet AMD and diabetic retinal disease [5] - The company also leverages its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain [6]